Diabesity Treatments Today and Tomorrow

American Diabetes Association. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S128-S139.

American Diabetes Association. 9. Pharmacologic Ap- proaches to Glycemic Treatment: standards of care in diabe- tes-2023. Diabetes Care. 2023;46(Suppl 1):S140-S157.

Mounjaro [Package Insert]. Indianapolis, IN: Eli Lilly and Company; September 2022.

Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities. 2022. Available at: https://inves-tor.lilly.com/news-releases/news-release-details/lilly-receives-us-fda-fast-track-designation-tirzepatide. Accessed January 5, 2023.

Byetta [Package Insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2022.

Victoza [Package Insert]. Plainsboro, NJ: Novo Nordisk; June 2022.

Saxenda [Package Insert]. Plainsboro, NJ: Novo Nordisk; June 2022.

Ozempic [Package Insert]. Plainsboro, NJ: Novo Nordisk; October 2022.

Wegovy [Package Insert]. Plainsboro, NJ: Novo Nordisk; December 2022.

FDA Drug Shortages Page. U.S.Food & Drug Administration website. https://www.fda.gov/drugs/drug-safety-and-availabil- ity/drug-shortages. Accessed January 12, 2023.

Jastreboff AM Aronne LJ Ahmad NN , et al. Tirzepa- tide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-216.

Knop FK Aroda VR doVale RD , et al. Oral Semaglutide 50 mg Taken Once Per Day in Adults with Overweight or Obesity (OASIS 1): a Randomised, Double-Blind, Placebo-Con-trolled, Phase 3 Trial [published online ahead of print, 2023 Jun 23]. Lancet. 2023;S0140-6736(23)01185-6. doi:10.1016/S0140-6736(23)01185-6

Aroda VR Aberle J Bardtrum L et al. Efficacy and Safety of Once-Daily Oral Semaglutide 25mg and 50mg Compared with 14mg in Adults with Type 2 Diabetes (PIONEER PLUS): a Multicentre, Randomised, Phase 3b Trial. Lancet.

Rybelsus [Package Insert]. Plainsboro, NJ: Novo Nordisk; January 2023.

Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (DREAMS-1) of Mazdutide (IBI362) in Chinese Pa- tients with Type 2 Diabetes. 2022. Available at: https://www.prnewswire.com/news-releases/innovent-announces-first-participant-dosed-in-a-phase-3-clinical-study-dreams-1-of-mazdutide-ibi362-in-chinese-patients-with-type-2-diabetes-301716408.html. Accessed January 14, 2023.

Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (GLORY-1) of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity. 2022. Available at: https:// www.prnewswire.com/news-releases/innovent-announces-first-participant-dosed-in-a-phase-3-clinical-study-glory-1-of-mazdutide-ibi362-in-chinese-adults-with-overweight-or-obesity-301676778.html. Accessed January 14, 2023.

Novo Nordisk Successfully Completes Phase 2 Trial with CagriSema in People with Type 2 Diabetes. 2022. Available at: https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=131155. Accessed January 2, 2023.

A Research Study to See How Well CagriSema Helps Peo- ple With Type 2 Diabetes and Excess Body Weight Lose Weight (REDEFINE-2). ClinicalTrials.gov identifier: NCT05394519. Updated January 10, 2023. Accessed January 11, 2023. https://clinicaltrials.gov/ct2/show/NCT05394519

Lilly Announces 2023 Financial Guidance, Plans to Launch up to Four New Medicines. 2022. Available at: https://inves-tor.lilly.com/news-releases/news-release-details/lilly-announc-es-2023-financial-guidance-plans-launch-four-new. Accessed January 5, 2023.

Boehringer Ingelheim and Zealand Pharma Announce Phase II Trial Showed 14.9% Weight Loss in People Living with Obesity or Overweight. 2023. Available at: https://www.boehringer-ingelheim.com/phase-ll-trial-results-in-obesity-or-overweight. Accessed August 1, 2023.

Sessa B Saxena A Schmeltz A. Analyst and Investor Call to Review Oral GLP-1 Data. A presentation at: The European Association for the Study of Diabetes (EASD) Annual Meeting; September 21, 2022; Stockholm.

Capozzi M DiMarchi RD Tschöp MH et al. Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes, En- docrine Reviews, Volume 39, Issue 5, October 2018, Pages 719-738. https://doi.org/10.1210/er.2018-00117

Symlin [Package Insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; June 2014.

Trulicity [Package Insert]. Indianapolis, IN: Eli Lilly and Company; December 2022.

Bydureon BCise [Package Insert]. Wilmington, DE: Astra- Zeneca Pharmaceuticals LP; December 2022.

Sanofi Website. Accessed January 4, 2023. https://www.adlyxin.com/

A study of IBI62 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise. ClinicalTrials.gov identifier: NCT05628311. Updated January 31, 2023. Accessed January 31, 2023. https://clinicaltrials.gov/ct2/show/ NCT05628311

A Study of LY3437943 in Participants With Type 2 Dia- betes. ClinicalTrials.gov identifier: NCT04867785. Updated November 8, 2022. Accessed December 26, 2022. https://clinicaltrials.gov/ct2/show/NCT04867785

Jastreboff AM Kaplan LM Frías JP , et al. Triple-Hormone-Re- ceptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972

Zvonko M Shweta U Mei Teng L , et al. LY3437943, A Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Provides Glucose Lowering and Weight Loss in Patients with T2DM After 12 weeks of Treatment. A presentation at: The European Association for the Study of Diabetes (EASD) Annual Meeting; September 21, 2022; Stockholm.

Frias JP Hsia S Eyde S , et al. Efficacy and Safety of Oral Orforglipron in Patients with Type 2 Diabetes: A Multicen-tre, Randomised, Dose-Response, Phase 2 Study. Lancet. 2023;402:472-83.doi:10.1016/S0140-6736(23)01302-8

Wharton S Blevins T Connery L , et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023. doi:10.1056/NEJMoa2302392

A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes. ClinicalTrials. gov identifier: NCT04153929. Updated November 29, 2022. Accessed January 4, 2023. https://clinicaltrials.gov/ct2/show/ results/NCT04153929

Zealand Pharma Announces Presentations at The Obesity Society Annual Meeting. 2022. Available at: https://www.globenewswire.com/newsrelease/2022/11/01/2545815/0/en/Zealand-Pharma-Announces-Presentations-at-The-Obesity-Society-Annual-Meeting.html. Accessed January 6, 2023.

A Study to Evaluate the Efficacy and Safety of PF- 06882961 in Adults With Obesity. ClinicalTrials.gov identifier: NCT04707313. Updated January 20, 2023. Accessed January 20, 2023. https://clinicaltrials.gov/ct2/show/NCT04707313

A 12-Week Titrate Study to Evaluate Safety, Tolerability and Pharmacodynamics of PF-06882961 In Adults With Type 2 Diabetes Mellitus And In Non-Diabetic Adults With Obesity. ClinicalTrials.gov identifier: NCT04617275. Updated December 8, 2022. Accessed January 5, 2023. https://clinicaltrials.gov/ct2/show/NCT04617275

A 16 Week Study to Evaluate the Efficacy and Safety of PF- 06882961 in Adults with Type 2 Diabetes Mellitus. ClinicalTri- als.gov identifier: NCT03985293. Updated June 30, 2022. Accessed January 5, 2023. https://clinicaltrials.gov/ct2/show/NCT03985293

GoodRx Website. Accessed April 20, 2023. https://www.goodrx.com/